Long-lasting anti-emetic effect of T-2328, a novel NK1 antagonist

Journal of Pharmacological Sciences

Volumn 107, Issue 2, 2008, Pages 151-158

  Watanabe, Yumi ^a   Okamoto, Masahito ^a   Ishii, Taketoshi ^a   Takatsuka, Satomi ^a   Taniguchi, Hiroyuki ^a   Nagasaki, Masaaki ^a   Saito, Akira ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Cisplatin; Emesis; Long acting; NK1

Indexed keywords

2 FLUORO 4' METHOXY 3' [[(2 PHENYL 3 PIPERIDINYL)AMINO]METHY](1,1' BIPHENYL) 4 CARBONITRILE; 5 AMINOVALERYLSUBSTANCE P [7-11][9 PROLINE 10 (N METHYLLEUCINE)]; CISPLATIN; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR AGONIST; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; SUBSTANCE P; T 2328;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TISSUE LEVEL; FERRET; GUINEA PIG; MALE; NONHUMAN; VOMITING;

EID: 46449084301     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08027FP     Document Type: Article

References (15)

1. Navari RM, Province PS. Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006;11:137-151.
2. Andrews PL, Davis CJ, Bingham S, Davidson HI, Hawthorn J, Maskell L. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol. 1990;68:325-345.
3. Aapro M. Optimising antiemetic therapy: what are the problems and how can they be overcome? Curr Med Res Opin. 2005;21:885-897.
4. 1 receptor in the brainstem in the development of emesis. J Pharmacol Sci. 2003;91:87-94.
5. Watson JW, Gonsalves SF, Fossa AA, McLean S, Seeger T, Obach S, et al. The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol. 1995;115:84-94.
6. Knox AP, Strominger NL, Battles AH, Carpenter DO. Behavioral studies of emetic sensitivity in the ferret. Brain Res Bull. 1993;31:477-484.
7. Tattersall FD, Rycroft W, Francis B, Pearce D, Merchant K, MacLeod AM, et al. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology. 1996;35:1121-1129.
8. Saito R, Suehiro Y, Ariumi H, Migita K, Hori N, Hashiguchi T, et al. Anti-emetic effects of a novel NK-1 receptor antagonist HSP-117 in ferrets. Neurosci Lett. 1998;254:169-172.
9. Tattersall FD, Rycroft W, Cumberbatch M, Mason G, Tye S, Williamson DJ, et al. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology. 2000;39:652-663.
10. Hesketh PJ, Grunberg SM, Gralla RJ, War DG, Roila F, de Wit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112-4119.
11. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090-3098.
12. 1 receptor. J Pharmacol Sci. 2008;106:121-127.
13. Rudd JA, Jordan CC, Naylor RJ. The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br J Pharmacol. 1996;119:931-936.
14. Rupniak NM, Williams AR. Differential inhibition of foot tapping and chromodacryorrhoea in gerbils by CNS penetrant and non-penetrant tachykinin NK1 receptor antagonists. Eur J Pharmacol. 1994;265:179-183.
15. Gralla, RJ. The clinical approach to chemotherapy-induced emesis. In: Reynolds DJM, Andrews PLR, Davis CJ, editors. Serotonin and the scientific basis of anti-emetic therapy. Oxford: Oxford Clinical Communications; 1995. p. 60-67.